Use of plasmapheresis to lower anti-AAV antibodies in nonhuman primates with pre-existing immunity to AAVrh74

Use of plasmapheresis to lower anti-AAV antibodies in nonhuman primates with pre-existing immunity to AAVrh74

Patients with pre-existing immunity to adeno-associated virus (AAV) are currently unable to receive systemic gene transfer therapies. In this nonhuman primate study, we investigated the impact of immunosuppression strategies on gene transfer therapy safety and efficacy and analyzed plasmapheresis as...

Full description

Bibliographic Details
Main Authors: Rachael A. Potter, Ellyn L. Peterson, Danielle Griffin, Grace Cooper Olson, Sarah Lewis, Kyle Cochran, Jerry R. Mendell, Louise R. Rodino-Klapac
Format: Article
Language:English
Published: Elsevier 2024-03-01
Series:Molecular Therapy: Methods & Clinical Development
Subjects:
antibodies
Duchenne muscular dystrophy
gene therapy
plasmapheresis
redosing
safety
Online Access:http://www.sciencedirect.com/science/article/pii/S2329050124000111

Internet

http://www.sciencedirect.com/science/article/pii/S2329050124000111

Similar Items